Overview

• Physician services provider's Q4 revenue beat analyst expectations

• Adjusted EBITDA for Q4 missed analyst expectations

• Same-unit revenue growth driven by improved collections and favorable payor mix

Outlook

• Pediatrix anticipates 2026 Adjusted EBITDA between $280 mln and $300 mln

Result Drivers

• SAME-UNIT REVENUE GROWTH - Driven by improved collections, favorable payor mix, and higher patient acuity, particularly in neonatology

• PRACTICE DISPOSITIONS - Net revenue decline due to practice dispositions, partially offset by same-unit revenue growth

• PATIENT SERVICE VOLUME DECLINE - Same-unit patient service volumes decreased by 2.7% in Q4

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for Pediatrix Medical Group Inc is $22.00, about 0.1% above its February 18 closing price of $21.97

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nBw99nhjFa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.